AbbVie Inc.: Growth Beyond Humira
Cashu Finance·5 min read

TL;DR
- AbbVie is diversifying its product portfolio post-Humira.
- Strong revenue growth driven by RINVOQ and SKYRIZI.
- Strategic acquisitions enhance AbbVie's market position.
AbbVie Inc. (ABBV) is experiencing a remarkable transformation as it adapts to market shifts following the patent expiration of its flagship drug, Humira. Initially, Humira's unparalleled success established AbbVie as a leading player in the biopharmaceutical industry, generating massive revenues through its effectiveness in treating autoimmune diseases. However, with the waves of biosimilars entering the market, AbbVie has been forced to restructure its business model, emphasizing innovation and strategic acquisitions to maintain its competitive edge.
The Legacy of Humira and Its Challenges
Humira has long been the cornerstone of AbbVie's business model, earning billions through treatments for rheumatoid arthritis and Crohn's disease. Yet, as the patent on Humira expired, competition intensified. The emergence of biosimilars has anticipated a significant decrease in Humira’s revenue, which recently fell to $683 million from nearly $1 billion last year. This 30.6% decline exemplifies the pressure AbbVie faces in a market increasingly crowded with more affordable alternatives.
To bolster its standing, AbbVie aims to redefine its product portfolio and accelerate the development of innovative therapies. This strategy is underscored by the recent acquisition of Apogee Therapeutics, aimed at enhancing AbbVie's immunology capabilities. Such moves signify AbbVie’s commitment to fortifying its position in the biopharmaceutical landscape, seeking to innovate and diversify beyond a reliance on any single product.

